spot difference
  • Sign In
  • Register
  • Cart (0)
Home > References > 2010 > Alterations of matrix metalloproteinases in healthy elderly with increased risk of prodromal Alzheimer's disease.

Alterations of matrix metalloproteinases in healthy elderly with increased risk of prodromal Alzheimer's disease.

Stomrud, E., Bjorkqvist, M., Janciauskiene, S., Minthon, L., Hansson, O.
Journal   Alzheimers Res Ther.
Species  
Analytes Measured   MMP-1 , MMP-3 total , MMP-9 , TIMP-1
Matrix Tested   Cerebrospinal fluid (CSF)
Year   2010
Volume   2
Page Numbers  
Application   Alzheimers
Abstract
INTRODUCTION: Matrix metalloproteinases (MMP) are believed to be involved in the pathologic processes behind Alzheimer's disease (AD). In this study, we aimed to examine the cerebrospinal fluid (CSF) levels of MMPs and tissue inhibitors of metalloproteinase-1 (TIMP-1) in individuals with AD dementia and cognitively healthy elderly individuals, and to investigate their relationship with established CSF biomarkers for Alzheimer's disease.

METHODS: CSF was collected from 38 individuals with AD dementia and 34 cognitively healthy elderly individuals. The CSF was analyzed for MMP-1, MMP-3, MMP-9, TIMP-1, beta-amyloid1-42 (Abeta42), total tau protein (T-tau) and phosphorylated tau protein (P-tau). MMP/TIMP-1 ratios were calculated. APOE genotype was determined for the participants.

RESULTS: AD patients had higher MMP-9/TIMP-1 ratios and lower TIMP-1 levels compared to cognitively healthy individuals. In AD patients, the MMP-9/TIMP-1 ratio correlated with CSF T-tau, a marker of neurodegeneration. Interestingly, the cognitively healthy individuals with risk markers for future AD, i.e. AD-supportive CSF biomarker levels of T-tau, P-tau and Abeta42 or the presence of the APOE epsilon4 allele, had higher CSF MMP-3 and MMP-9 levels and higher CSF MMP-3/TIMP-1 ratios compared to the healthy individuals without risk markers. The CSF levels of MMP-3 and -9 in the control group also correlated with the CSF T-tau and P-tau levels.

CONCLUSIONS: This study indicates that MMP-3 and MMP-9 might be involved in early pathogenesis of AD and that MMPs could be associated with neuronal degeneration and formation of neurofibrillary tangles even prior to development of overt cognitive dysfunction.

View Publications
View Publications

Related Products

R-PLEX Human MMP-9 (active) Antibody Set
MMP-9 (active) | Human
R-PLEX Human MMP-9 (active) Assay
MMP-9 (active) | Human
Singleplex
U-PLEX Human MMP-1 Antibody Set
MMP-1 | Human
U-PLEX Human MMP-1 384-well Assay
MMP-1 | Human
Singleplex
U-PLEX Metastasis Combo 1 (human)
E-Selectin, MMP-1, MMP-2, MMP-7, MMP-9 (total), P-Selectin, VEGFR-1/Flt-1 | Human
Multiplex
U-PLEX Human MMP-1 Assay
MMP-1 | Human
Singleplex
R-PLEX Mouse TIMP-1 Antibody Set
TIMP-1 | Mouse
R-PLEX Mouse TIMP-1 Assay
TIMP-1 | Mouse
Singleplex
R-PLEX Human MMP-3 Assay
MMP-3 (total) | Human
Singleplex
R-PLEX Human TIMP-1 Assay
TIMP-1 | Human
Singleplex
R-PLEX Rat TIMP-1 Assay
TIMP-1 | Rat
Singleplex
R-PLEX Mouse MMP-3 (total) Assay
MMP-3 (total) | Mouse
Singleplex
R-PLEX Mouse MMP-3 (total) Antibody Set
MMP-3 (total) | Mouse
R-PLEX Rat TIMP-1 Antibody Set
TIMP-1 | Rat
R-PLEX Human TIMP-1 Antibody Set
TIMP-1 | Human
R-PLEX Human MMP-3 Antibody Set
MMP-3 (total) | Human
Muscle Injury Panel 2 Rat Kit
CK, TIMP-1 | Rat
Multiplex
Human TIMP-1 Kit
TIMP-1 | Human
Singleplex
Human MMP 3-Plex Ultra-Sensitive Kit
MMP-1, MMP-3 (total), MMP-9 (active) | Human
Multiplex
Human MMP-3 Ultra-Sensitive Kit
MMP-3 (total) | Human
Singleplex
Human MMP-9 Ultra-Sensitive Kit
MMP-9 (active) | Human
Singleplex
Human MMP-1 Ultra-Sensitive Kit
MMP-1 | Human
Singleplex
U-PLEX Immuno-Oncology Group 1 (human) Assays
APRIL/TNFSF13, BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD28, CD40L (soluble), CD276/B7-H3, CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FLT3L, Fractalkine, Galectin-9, G-CSF, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO-α, HAVCR2/TIM-3, HVEM/TNFRSF14, I-309, ICOS, ICOS-L/B7-H2, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, IP-10, I-TAC, LAG3, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1α, MIP-1β, MIP-5, MMP-1, MMP-2, MMP-7, MMP-9 (total), Nectin-4, OX40/TNFRSF4, PD1 (epitope 1), PD1 (epitope 2), PD-L1 (epitope 1), PD-L1 (epitope 2), PD-L2, Pentraxin 3, Perforin, PlGF, proMMP-9, P-Selectin, RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, Tie-2, TIGIT, TLR1, TNF-α, TNF-β, TNF-RI, TNF-RII, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/Flt-1, YKL-40 | Human
Multiplex
U-PLEX Immuno-Oncology Group 1 (human) Assays
APRIL/TNFSF13, BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD28, CD40L (soluble), CD276/B7-H3, CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FLT3L, Fractalkine, Galectin-9, G-CSF, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO-α, HAVCR2/TIM-3, HVEM/TNFRSF14, I-309, ICOS, ICOS-L/B7-H2, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, IP-10, I-TAC, LAG3, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1α, MIP-1β, MIP-5, MMP-1, MMP-2, MMP-7, MMP-9 (total), Nectin-4, OX40/TNFRSF4, PD1 (epitope 1), PD1 (epitope 2), PD-L1 (epitope 1), PD-L1 (epitope 2), PD-L2, Pentraxin 3, Perforin, PlGF, proMMP-9, P-Selectin, RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, Tie-2, TIGIT, TLR1, TNF-α, TNF-β, TNF-RI, TNF-RII, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/Flt-1, YKL-40 | Human
Multiplex
U-PLEX Immuno-Oncology Group 1 (human) 384-well Assays
BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD28, CD40L (soluble), CD276/B7-H3, CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, FGF (basic), FLT3L, Fractalkine, G-CSF, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO-α, HAVCR2/TIM-3, I-309, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, IP-10, I-TAC, LAG3, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1α, MIP-1β, MIP-5, OX40/TNFRSF4, PD1 (epitope 1), PD1 (epitope 2), PD-L1 (epitope 1), PD-L2, PlGF, RANKL/TNFSF11, Tie-2, TIGIT, TLR1, TNF-α, TNF-β, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, YKL-40 | Human
Multiplex
Browse Our Products

By Analytes
By Applications
Search
Customer Service/Orders


Scientific/Technical Support


Instrument Support


Company Headquarters